Barra lateral de artículos

Revistas_275_300x300_portada201430.JPG
Enviado
4 mayo 2020
Publicado
30 junio 2020
Descargar
pdf html xml
Estadística
Leer contador : 1146 Descargar : 564

Descargas

Los datos de descargas todavía no están disponibles.

Métricas

Cargando métricas ...

Contenido del artículo principal

Resumen

En diciembre de 2019 se identificó en China una nueva subespecie de coronavirus al que denominaron SARS-CoV-2, responsable de la enfermedad posterior a la que la OMS llamó COVID-19. La enfermedad se ha propagado rápidamente provocando una pandemia mundial. Todavía se desconoce mucho del SARS-CoV-2, pero las primeras investigaciones respaldan la hipótesis de que la gravedad de la COVID-19 viene condicionada por la respuesta hiperinflamatoria que se produce en nuestro organismo al contacto con el SARS-CoV-2. La gravedad del cuadro se relaciona con la insuficiencia respiratoria que provoca, no obstante, existen estudios que no limitan la afectación pulmonar. Investigaciones apuntan a que el mecanismo de acceso del SARS-CoV-2 al organismo está muy relacionado con la enzima ACE2. Enzima que entre otros tejidos, se puede encontrar en el epitelio de las células tubulares renales. Esta es la causa por la que existen datos de pacientes con COVID-19 que tienen una gran afectación en la función renal y pueden cursar con IRA (factor de mal pronóstico). Por este motivo, unido a que las comorbilidades asociadas con una mayor mortalidad durante la infección COVID-19 son comunes en los pacientes con enfermedad renal crónica, creemos necesario conocer los resultados que aportan los diferentes estudios realizados sobre esa materia.

Palabras clave

COVID-19 SARS-CoV-2 enfermedades renales revisión diálisis trasplante riñón

Detalles del artículo

Licencia

Aviso de derechos de autor/a

© Los autores ceden de forma no exclusiva los derechos de explotación de los trabajos publicados y consiente en que su uso y distribución se realice con la Licencia Creative Commons Atribución - No comercial 4.0 Internacional (CC BY-NC 4.0). Puede consultar desde aquí la versión informativa y el texto legal de la licencia. Esta circunstancia ha de hacerse constar expresamente de esta forma cuando sea necesario.

 

Cómo citar
1.
Hidalgo-Blanco M Ángel, Andreu-Periz D, Moreno-Arroyo MC. COVID-19 en el enfermo renal. Revisión breve. Enferm Nefrol [Internet]. 2020 [consultado 18 Abr 2024];23(2):[aprox. 10 p.]. Disponible en: https://enfermerianefrologica.com/revista/article/view/3534
Descargar cita
Endnote/Zotero/Mendeley (RIS)
BibTeX
Crossref
Scopus
Google Scholar
Europe PMC

Referencias

  1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020;382:727-33. DOI: https://doi.org/10.1056/NEJMoa2001017
  2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb;395(10224):565-74. DOI: https://doi.org/10.1016/S0140-6736(20)30251-8
  3. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829-38. DOI: https://doi.org/10.1016/j.kint.2020.03.005
  4. Li-sheng Wang , Yi-ru Wang , Da-wei Ye , Qing-quan Liu. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents. 2020 Mar:105948. [En prensa]. DOI: https://doi.org/10.1016/j.ijantimicag.2020.106137
  5. Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020 Feb. [En prensa]. DOI: https://doi.org/10.1002/jmv.25722
  6. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host & Microbe. 2020 Feb;27(3):325-8. DOI: https://doi.org/10.1016/j.chom.2020.02.001
  7. Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020;27(2):taaa021. DOI: https://doi.org/10.1093/jtm/taaa021
  8. Michaels MG, La Hoz RM, Danziger-Isakov L, Blumberg EA, Kumar D. Green M, et al. Coronavirus disease 2019: Implications of emerging infections for transplantation. Am J Transplant. 2020 Feb. [En prensa].
  9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. DOI: https://doi.org/10.1016/S0140-6736(20)30183-5
  10. Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. On behalf of the “Brescia Renal COVID Task Force, Management Of Patients On Dialysis And With Kidney Transplant During SARS-COV-2 (COVID-19) Pandemic In Brescia, Italy. Kidney Int Rep. 2020 Abr. [En prensa].
  11. Wei LQ, Rong ZK, Gui L, Shan RD. CT diagnosis of renal vein thrombosis in nephrotic syndrome. J Comput Assist Tomogr. 1991;15(3):454-7. DOI: https://doi.org/10.1097/00004728-199105000-00020
  12. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 May;46(5):846-8. DOI: https://doi.org/10.1007/s00134-020-05991-x
  13. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) COVID 19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar;395(10229):1033-4. DOI: https://doi.org/10.1016/S0140-6736(20)30628-0
  14. Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014 Abr;383(9927):1503-16. DOI: https://doi.org/10.1016/S0140-6736(13)61048-X
  15. Karakike E, Giamarellos-Bourboulis EJ. Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis. Front Immunol 2019;10:55. DOI: https://doi.org/10.3389/fimmu.2019.00055
  16. Seguin A, Galicier L, Boutboul D, Lemiale V, Azoulay E. Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis. Chest 2016;149:1294-301. DOI: https://doi.org/10.1016/j.chest.2015.11.004
  17. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395(10223): 473-5. DOI: https://doi.org/10.1016/S0140-6736(20)30317-2
  18. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 2014;66(9)2613-20. DOI: https://doi.org/10.1002/art.38690
  19. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARSCoV- 2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-80. DOI: https://doi.org/10.1016/j.cell.2020.02.052
  20. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020 Mar; 367(6485):1444-8. DOI: https://doi.org/10.1126/science.abb2762
  21. Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARSCoV- 2. J Med Virol. 2020 Feb. [En prensa]. DOI: https://doi.org/10.1002/jmv.25726
  22. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020 Feb;367(6483):1260-3. DOI: https://doi.org/10.1126/science.abb2507
  23. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 2020;94(7):e00127-20. DOI: https://doi.org/10.1128/JVI.00127-20
  24. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020 Mar;63(3):457-60. DOI: https://doi.org/10.1007/s11427-020-1637-5
  25. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020 Mar. [En prensa]. DOI: https://doi.org/10.1007/s11684-020-0754-0
  26. Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol. 2006 Nov;17(11):3067-75. DOI: https://doi.org/10.1681/ASN.2006050423
  27. Wang L, Li X, Chen H, Yan S, Li D, Li Y, Gong Z. Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China. Am J Nephrol. 2020;51(5):343-8. DOI: https://doi.org/10.1159/000507471
  28. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19 N Engl J Med. 2020;382:1653-9. DOI: https://doi.org/10.1056/NEJMsr2005760
  29. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus- Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. DOI: https://doi.org/10.1001/jama.2020.1585
  30. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med 2020; 382:1708-20. DOI: https://doi.org/10.1056/NEJMoa2002032
  31. Rabb H. Kidney diseases in the time of COVID-19: major challenges to patientcare. J Clin Invest. 2020 May. pii: 138871. [En prensa]. DOI: https://doi.org/10.1172/JCI138871
  32. Diao B, Wang C, Wang R, Feng Z, Tan Y, Wang H, et al. Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. medRxiv. 2020 Mar. [En prensa]. DOI: https://doi.org/10.1101/2020.03.04.20031120
  33. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney impairment is associated with in-hospital death of COVID-19 patients. medRxiv. 2020 Feb. [En prensa]. DOI: https://doi.org/10.1101/2020.02.18.20023242
  34. Zhang WR, and Parikh CR. Biomarkers of Acute and Chronic Kidney Disease. Annu Rev Physiol. 2019;81:309-33. DOI: https://doi.org/10.1146/annurev-physiol-020518-114605
  35. Ma Y, Diao B, Lv X, Zhu J, Liang W, Wendou LL, et al. 2019 novel coronavirus disease in hemodialysis (HD) patients: Report from one HD center in Wuhan, China. medRxiv. 2020 Feb. [En prensa]. DOI: https://doi.org/10.1101/2020.02.24.20027201
  36. Wang R, Liao C, He H, Hu C, Wei Z, Hong Z, et al. COVID-19 in Hemodialysis Patients: A Report of 5 Cases. Am J Kidney Dis. 2020 Mar. pii: S0272-6386(20)30612-0. [En prensa]. DOI: https://doi.org/10.1053/j.ajkd.2020.03.009
  37. Guillen E, Pineiro GJ, Revuelta I, Rodriguez D, Bodro M, Moreno A, et al. Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation?. Am J Transplant. 2020 Mar. [En prensa]. DOI: https://doi.org/10.1111/ajt.15874
  38. Gandolfini I, Delsante M, Fiaccadori E, Zaza G, Manenti L, Antoni AD, et al. COVID-19 in Kidney Transplant Recipients. Am J Transplant. 2020;10.1111/ajt.15891. [En prensa]. DOI: https://doi.org/10.1111/ajt.15891
  39. Zhu L, Xu X, Ma K, Yang K, Guan H, Chen S, et al. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. Am J Transplant. 2020 Mar. [En prensa]. DOI: https://doi.org/10.1111/ajt.15869
  40. Cohen-Hagai K, Rozenberg I, Korzets Z, Zitman-Gal T, Einbinder Y, Benchetrit S. Upper Respiratory Tract Infection among Dialysis Patients. Isr Med Assoc J. 2016;18:557-60.
  41. Sibbel S, Sato R, Hunt A, Tuernne W, Brurnelli SM. The clinical and economic burden of pneumonia in patients enrolled in Medicare receiving dialysis: a retrospective, observational cohort study. BMC Nephrol. 2016;17:199. DOI: https://doi.org/10.1186/s12882-016-0412-6
  42. Trujillo H, Caravaca-Fontán F, Sevillano Á, Gutiérrez E, Caro J, Gutiérrez E, et al. SARS-CoV-2 Infection in Hospitalized Patients with Kidney Disease. Kidney Int Rep. May 2020. [En prensa]. DOI: https://doi.org/10.1016/j.ekir.2020.04.024
  43. Rombolà G, Brunini F. COVID-19 and dialysis: why we should be worried. J Nephrol. 2020 Abr;22:1-3. DOI: https://doi.org/10.1007/s40620-020-00737-w
  44. Naicker S, Yang CW, Hwang SJ, Liu BC, Chen JH, Jha V. The Novel Coronavirus 2019 epidemic and kidneys. Kidney Int. 2020;97(5):824-28. DOI: https://doi.org/10.1016/j.kint.2020.03.001
  45. Brodie D, Curtis JR, Vincent JL, Bakker J, Brown CE, Creteur J, et al. Participants in the Round Table Conference. Treatment limitations in the era of ECMO. Lancet Respir Med. 2017 Oct;5(10):769-70. DOI: https://doi.org/10.1016/S2213-2600(17)30263-1
  46. Noah MA, Peek GJ, Finney SJ, Griffiths MJ, Harrison DA, Grieve R, et al. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). JAMA. 2011 Oct; 306(15):1659-68. DOI: https://doi.org/10.1001/jama.2011.1471
  47. DeLaney E, Smith MJ, Harvey BT, Pelletier KJ, Aquino MP, Stone JM, et al. Extracorporeal life support for pandemic influenza: the role of extracorporeal membrane oxygenation in pandemic management. J Extra Corpor Technol. 2010 Dic;42(4):268-80. DOI: https://doi.org/10.1051/ject/201042268
  48. Lim CC, Tan CS, Kaushik M, Tan HK. Initiating acute dialysis at earlier Acute Kidney Injury Network stage in critically ill patients without traditional indications does not improve outcome: a prospective cohort study. Nephrology (Carlton). 2015;20:148-54. DOI: https://doi.org/10.1111/nep.12364
  49. Rombolà G, Heidempergher M, Pedrini L, Farina M, Aucella F, Messa P, et al. Practical indications for the prevention and management of SARS-CoV2 in ambulatory dialysis patients: lessons from the first phase of the epidemics in Lombardy. J Nephrol. 2020 Abr;33(2):193-6. DOI: https://doi.org/10.1007/s40620-020-00727-y
  50. Ikizler TA. COVID-19 and dialysis units: what do we know now and what should we do?. Am J Kidney Dis. 2020 Mar. [En prensa]. DOI: https://doi.org/10.1053/j.ajkd.2020.03.008
  51. Bomback AS, Canetta PA, Ahn W, Ahmad SB, Radhakrishnan J, Appel GB. How COVID-19 Has Changed the Management of Glomerular Diseases. CJASN. 2020 May. [En prensa]. DOI: https://doi.org/10.2215/CJN.04530420
  52. Bussalino E, De Maria A, Russo R, Paoletti E. Immunosuppressive therapy maintenance in a kidney transplant recipient SARS-CoV-2 pneumonia: a case report. Am J Transplant. 2020 Abr. [En prensa]. DOI: https://doi.org/10.1111/ajt.15920
  53. Michaels MG, La Hoz RM, Danziger-Isakov L, Blumberg EA, Kumar D, Green M, et al. Coronavirus disease 2019: Implications of emerging infections for transplantation. Am J Transplant. 2020 Feb. [En prensa]. DOI: https://doi.org/10.1111/ajt.15832
  54. Alberici F, Delbarba E, Manenti C, Econimo L Valerio F, Pola A, et al. Management Of Patients On Dialysis And With Kidney Transplant During SARS-COV-2 (COVID-19) Pandemic In Brescia, Italy. Kidney Int Rep. 2020 Abr. [En prensa]. DOI: https://doi.org/10.1016/j.ekir.2020.04.001
  55. Fernández-Ruiz M, Andrés A, Loinaz C, Delgado JF, López-Medrano F, San Juan R, et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transplant. 2020 Abr. [En prensa]. DOI: https://doi.org/10.1111/ajt.15929
  56. Liu B1, Wang Y, Zhao Y, Shi H, Zeng F, Chen Z. Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient. Am J Transplant. 2020 Abr. [En prensa]. DOI: https://doi.org/10.1111/ajt.15901
  57. Seminari E, Colaneri M, Sambo M, Gallazzi I, Di Matteo A, Roda S, et al. SARS Cov2 infection in a renal transplanted patients. A case report. Am J Transplant. 2020 Abr. [En prensa]. DOI: https://doi.org/10.1111/ajt.15902
  58. Li F, Cai J, Dong N. First cases of COVID-19 in heart transplantation from China. J Heart Lung Transplant. 2020 Mar. [En prensa]. DOI: https://doi.org/10.1016/j.healun.2020.03.006
  59. Chen S, Yin Q, Shi H, Du D, Chang S, Ni L, et al. A familial cluster, including a kidney transplant recipient, of Coronavirus Disease 2019 (COVID-19) in Wuhan, China. Am J Transplant. 2020 Abr. [En prensa]. DOI: https://doi.org/10.1111/ajt.15903
  60. Huang J, Lin H, Wu Y, Fang Y, Kumar R, Chen G, et al. COVID-19 in post-transplantation patients - report of two cases. Am J Transplant. 2020 Abr. [En prensa]. DOI: https://doi.org/10.1111/ajt.15896
  61. Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube G, Ratner LE, et al., COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US epicenter. Am J Transplant. 2020 Abr. [En prensa].
  62. Antonio R, Silvia M. Immunosuppression drug-related and clinical manifestation of Coronavirus disease 2019: a therapeutical hypothesis. Am J Transplant. 2020 Abr. [En prensa].
  63. Fishman, J.A. Infection in Organ Transplantation. Am J Transplant 2017;17(4): 856-79. DOI: https://doi.org/10.1111/ajt.14208
  64. Johnson KM, Belfer JJ, Peterson GR, Boelkins MR, Dumkow LE. Managing COVID-19 in Renal Transplant Recipients: A Review of Recent Literature and Case Supporting Corticosteroid-sparing Immunosuppression. Pharmacotherapy. 2020;10.1002/phar.2410. [En prensa]. DOI: https://doi.org/10.1002/phar.2410

Artículos más leídos del mismo autor/a

1 2 3 > >> 

Artículos similares

También puede {advancedSearchLink} para este artículo.